Related Experiment Videos
Two or three insulin injections in adolescence?
Archives of Disease in Childhood
|February 1, 1986
Summary
Delaying evening insulin in adolescents with type 1 diabetes did not improve overall blood sugar control (HbA1c). Seasonal factors significantly impacted glucose levels more than this insulin timing adjustment.
Area of Science:
- Pediatrics
- Endocrinology
- Metabolic Disorders
Background:
- Morning hyperglycemia is a persistent challenge for adolescents with type 1 diabetes on conventional insulin therapy.
- Optimizing insulin timing is crucial for managing blood glucose fluctuations in this population.
Purpose of the Study:
- To evaluate the impact of delaying evening intermediate-acting insulin administration to bedtime on glycemic control in adolescents with type 1 diabetes.
- To compare a three-injection regimen (delayed evening insulin) with conventional regimens.
Main Methods:
- A one-year crossover study involving 18 adolescents with type 1 diabetes.
- Participants were switched between a conventional insulin regimen and a regimen with delayed evening intermediate-acting insulin (given at bedtime instead of before the evening meal).
- Glycosylated hemoglobin (HbA1c) concentrations and blood glucose levels were monitored.
Main Results:
- The delayed insulin regimen resulted in slightly higher early nighttime blood glucose but lower morning concentrations, with no significant change in overall HbA1c.
- Seasonal variations accounted for a larger proportion of the variance in HbA1c than the insulin regimen change.
- The frequency of hypoglycemic episodes remained unchanged between the two regimens.
Conclusions:
- Adjusting the timing of evening intermediate-acting insulin to bedtime does not significantly improve glycemic control (HbA1c) in adolescents with type 1 diabetes.
- Seasonal variations play a more substantial role in glycemic control variability than changes in conventional insulin regimens.
- Intensified monitoring and medical attention may be necessary to further improve metabolic control in this patient group.